Pulmonary alveolar proteinosis and granulocyte/macrophage-colony stimulating factor (GM-CSF) inhalation

Bibliography

• Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med. 2002;166:215–235.
   PubMed Web of Science ®Google Scholar
• Trapnell BC, Whitsett JA, Nakata K. Pulmonary alveolar proteinosis. N Engl J Med. 2003;349:2527–2539.
   PubMed Web of Science ®Google Scholar
• Inoue Y, Trapnell BC, Tazawa R, et al. Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med. 2008;177:752–762.
   PubMed Web of Science ®Google Scholar
• Tanaka N, Watanabe J, Kitamura T, et al. Lungs of patients with idiopathic pulmonary alveolar proteinosis express a factor which neutralizes granulocyte-macrophage colony stimulating factor. FEBS Lett. 1999;442:246–250.
   PubMed Web of Science ®Google Scholar
• Kitamura T, Tanaka N, Watanabe J, et al. Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J Exp Med. 1999;190:875–880.
   PubMed Web of Science ®Google Scholar
• Kitamura T, Uchida K, Tanaka N, et al. Serological diagnosis of idiopathic pulmonary alveolar proteinosis. Am J Respir Crit Care Med. 2000;162:658–662.
   PubMed Web of Science ®Google Scholar
• Dirksen U, Nishinakamura R, Groneck P, et al. Human pulmonary alveolar proteinosis associated with a defect in GM-CSF/IL-3/IL-5 receptor common beta chain expression. J Clin Invest. 1997;100:2211–2217.
   PubMed Web of Science ®Google Scholar
• Dranoff G, Crawford AD, Sadelain M, et al. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science. 1994;264((5159)):713–716.
   PubMed Web of Science ®Google Scholar
• Stanley E, Lieschke GJ, Grail D, et al. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci USA. 1994;91:5592–5596.
   PubMed Web of Science ®Google Scholar
• Uchida K, Nakata K, Trapnell BC, et al. High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis. Blood. 2004;103:1089–1098.
   PubMed Web of Science ®Google Scholar
• Sakagami T, Uchida K, Suzuki T, et al. Human GM-CSF autoantibodies and reproduction of pulmonary alveolar proteinosis. N Engl J Med. 2009;361:2679–2681.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Dunn AR, Vincent JM, et al. Efficacy of granulocyte-macrophage colony-stimulating factor in acquired alveolar proteinosis. N Engl J Med. 1996;335:1924–1925.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Presneill JJ, Schoch OD, et al. Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis. Am J Respir Crit Care Med. 2001;163:524–531.
   PubMed Web of Science ®Google Scholar
• Kavuru MS, Sullivan EJ, Piccin R, et al. Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis. Am J Respir Crit Care Med. 2000;161:1143–1148.
   PubMed Web of Science ®Google Scholar
• Venkateshiah SB, Yan TD, Bonfield TL, et al. An open-label trial of granulocyte macrophage colony stimulating factor therapy for moderate symptomatic pulmonary alveolar proteinosis. Chest. 2006;130:227–237.
   PubMed Web of Science ®Google Scholar
• Anderson PM, Markovic SN, Sloan JA, et al. Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases. Clin Cancer Res. 1999;5:2316–2323.
   PubMed Web of Science ®Google Scholar
• Wylam ME, Ten RM, Katzmann JA, et al. Aerosolized GM-CSF improves pulmonary function in idiopathic pulmonary alveolar proteinosis. Am J Respir Crit Care Med. 2000;161:A889.
   Google Scholar
• Tazawa R, Hamano E, Arai T, et al. Granulocyte-macrophage colony-stimulating factor and lung immunity in pulmonary alveolar proteinosis. Am J Respir Crit Care Med. 2005;171:1142–1149.
   PubMed Web of Science ®Google Scholar
• Tazawa R, Trapnell BC, Inoue Y, et al. Inhaled granulocyte/macrophage-colony stimulating factor as therapy of pulmonary alveolar Proteinosis. Am J Respir Crit Care Med. 2010;181:1345–1354.
   PubMed Web of Science ®Google Scholar
• Hansen G, Hercus TR, McClure BJ, et al. The structure of the GM-CSF receptor complex reveals a distinct mode of cytokine receptor activation. Cell. 2008;134:496–507.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Sakagami T, Rubin BK, et al. Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA. J Exp Med. 2008;205:2703–2710.
   PubMed Web of Science ®Google Scholar
• Nakata K, Akagawa KS, Fukayama M, et al. Granulocyte-macrophage colony-stimulating factor promotes the proliferation of human alveolar macrophages in vitro. J Immunol. 1991;147:1266–1272.
   PubMed Web of Science ®Google Scholar
• Wright JR, Youmans DC. Degradation of surfactant lipids and surfactant protein A by alveolar macrophages in vitro. Am J Physiol. 1995;268(5 Pt 1):L772–80.
   PubMed Web of Science ®Google Scholar
• Shibata Y, Berclaz PY, Chroneos ZC, et al. GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity. 2001;15:557–567.
   PubMed Web of Science ®Google Scholar
• Rose RM, Kobzik L, Dushay K, et al. The effect of aerosolized recombinant human granulocyte macrophage colony-stimulating factor on lung leukocytes in nonhuman primates. Am Rev Respir Dis. 1992;146(5 Pt 1):1279–1286.
   PubMed Web of Science ®Google Scholar
• Reed JA, Ikegami M, Cianciolo ER, et al. Aerosolized GM-CSF ameliorates pulmonary alveolar proteinosis in GM-CSF-deficient mice. Am J Physio Lung Cell Mol Physiol. 1999;276:L556–63.
   PubMed Web of Science ®Google Scholar
• Price A, Manson D, Cutz E, et al. Pulmonary alveolar proteinosis associated with anti-GM-CSF antibodies in a child: successful treatment with inhaled GM-CSF. Pediatr Pulmonol. 2006;41:367–370.
   PubMed Web of Science ®Google Scholar
• Yamamoto H, Yamaguchi E, Agata H, et al. A combination therapy of whole lung lavage and GM-CSF inhalation in pulmonary alveolar proteinosis. Pediatr Pulmonol. 2008;43:828–830.
   PubMed Web of Science ®Google Scholar
• Robinson TE, Trapnell BC, Goris ML, et al. Quantitative analysis of longitudinal response to aerosolized granulocyte-macrophage colony-stimulating factor in two adolescents with autoimmune pulmonary alveolar proteinosis. Chest. 2009;135:842–848.
   PubMed Web of Science ®Google Scholar
• Wylam ME, Ten R, Prakash UB, et al. Aerosol granulocyte–macrophage colony stimulating factor for pulmonary alveolar proteinosis. Eur Respir J. 2006;27:585–593.
   PubMed Web of Science ®Google Scholar
• Markovic SN, Suman VJ, Nevala WK, et al. A dose-escalation study of aerosolized sargramostim in the treatment of metastatic melanoma: an NCCTG Study. Am J Clin Oncol. 2008;31:573–579.
   PubMed Web of Science ®Google Scholar
• Arndt CA, Koshkina NV, Inwards CY, et al. Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children’s Oncology Group. . Clin Cancer Res. 2010;16:4024–4030.
   PubMed Web of Science ®Google Scholar
• Luisetti M, Kroneberg P, Suzuki T, et al. Physical properties, lung deposition modeling, and bioactivity of recombinant GM-CSF aerosolised with a highly efficient nebulizer. Pulm Pharmacol Ther. 2011;24:123–127.
   PubMed Web of Science ®Google Scholar
• Chen GH, Curtis JL, Mody CH, et al. Effect of granulocyte-macrophage colony-stimulating factor on rat alveolar macrophage anticryptococcal activity in vitro. J Immunol. 1994;152:724–734.
   PubMed Web of Science ®Google Scholar
• Herold S, Hoegner K, Vadász I, et al. Inhaled granulocyte/macrophage colony-stimulating factor as treatment of pneumonia-associated acute respiratory distress syndrome. Am J Respir Crit Care Med. 2014;189:609–611.
   PubMed Web of Science ®Google Scholar
• Tazawa R, Inoue Y, Arai T, et al. Duration of benefit in patients with autoimmune pulmonary alveolar proteinosis after inhaled granulocyte-macrophage colony-stimulating factor therapy. Chest. 2014;145:729–737.
   PubMed Web of Science ®Google Scholar
• Ullenhag G, Bird C, Ragnhammar P, et al. Incidence of GM-CSF antibodies in cancer patients receiving GM-CSF for immunostimulation. Clin Immunol. 2001;99:65–74.
   PubMed Web of Science ®Google Scholar
• Wadhwa M, Skog AL, Bird C, et al. Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF. Clin Cancer Res. 1999;5:1353–1361.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Arumugam P, Sakagami T, et al. Pulmonary macrophage transplantation therapy. Nature. 2014;514(7523):450–454.
   PubMed Web of Science ®Google Scholar
• Arai T, Hamano E, Inoue Y, et al. Serum neutralizing capacity of GM-CSF reflects disease severity in a patient with pulmonary alveolar proteinosis successfully treated with inhaled GM-CSF. Respir Med. 2004;98:1227–1230.
   PubMed Web of Science ®Google Scholar
• Campo I, Kadija Z, Mariani F, et al. Pulmonary alveolar proteinosis: diagnostic and therapeutic challenges. Multidiscip Respir Med. 2012;7:4.
   PubMed Web of Science ®Google Scholar
• Yu H, Sun X, Wang Y, et al. Whole lung lavage combined with Granulocyte-macrophage colony stimulating factor inhalation for an adult case of refractory pulmonary alveolar proteinosis. BMC Pulm Med. 2014;14:87.
   PubMed Web of Science ®Google Scholar
• Akasaka K, Tanaka T, Maruyama T, et al. A mathematical model to predict protein wash out kinetics during whole-lung lavage in autoimmune pulmonary alveolar proteinosis. Am J Physiol Lung Cell Mol Physiol. 2015;308:L105–17.
   PubMed Web of Science ®Google Scholar